TxA2	O
,	O
generated	O
from	O
arachidonic	O
acid	O
by	O
cyclooxygenase	O
1	O
(	O
COX	O
-	O
1	O
)	O
and	O
Tx	O
synthase	O
,	O
further	O
amplifies	O
platelet	B-Cell
activation	O
.	O

COX	O
-	O
1	O
converts	O
arachidonic	O
acid	O
into	O
prostaglandin	O
endoperoxides	O
PGG2	O
and	O
PGH2	O
,	O
the	O
latter	O
being	O
,	O
in	O
turn	O
,	O
transformed	O
by	O
Tx	O
synthase	O
into	O
TxA2	O
,	O
a	O
potent	O
amplifier	O
of	O
platelet	B-Cell
aggregation	O
with	O
vasoconstrictive	O
properties	O
.	O

At	O
the	O
site	B-Multi-tissue_structure
of	O
the	O
atheroma	B-Pathological_formation
rupture	O
,	O
platelet	B-Cell
-	O
released	O
TxA2	O
leads	O
to	O
downstream	O
micro	B-Tissue
-	I-Tissue
vessel	I-Tissue
contraction	O
and	O
thrombus	B-Pathological_formation
propagation	O
(	O
7	O
)	O
.	O

In	O
addition	O
to	O
its	O
role	O
in	O
coagulation	O
,	O
thrombin	O
at	O
extremely	O
low	O
concentrations	O
is	O
one	O
of	O
the	O
major	O
platelet	B-Cell
activators	O
(	O
8	O
)	O
.	O

Human	O
platelets	B-Cell
express	O
two	O
cell	B-Cellular_component
surface	I-Cellular_component
G	O
-	O
protein	O
-	O
coupled	O
protease	O
-	O
activated	O
receptors	O
(	O
PARs	O
)	O
for	O
thrombin	O
:	O
PAR	O
-	O
1	O
and	O
PAR	O
-	O
4	O
.	O

By	O
binding	O
the	O
hirudin	O
-	O
like	O
extracellular	B-Immaterial_anatomical_entity
amino	O
terminal	O
domain	O
(	O
the	O
so	O
-	O
called	O
thrombin	O
receptor	O
)	O
,	O
thrombin	O
activates	O
platelets	B-Cell
and	O
smooth	B-Cell
muscle	I-Cell
cells	I-Cell
,	O
thus	O
promoting	O
platelet	B-Cell
pro	O
-	O
coagulant	O
activity	O
,	O
shape	O
change	O
,	O
secretion	O
and	O
release	O
of	O
agonists	O
(	O
ADP	O
and	O
TxA2	O
)	O
,	O
expression	O
of	O
P	O
-	O
selectin	O
,	O
activation	O
of	O
the	O
alphaIIbbeta3	O
integrin	O
receptor	O
,	O
and	O
aggregation	O
.	O

Thrombin	O
also	O
binds	O
to	O
GpIbalpha	O
on	O
the	O
surface	B-Cellular_component
of	O
platelets	B-Cell
,	O
thought	O
to	O
act	O
as	O
a	O
co	O
-	O
factor	O
that	O
localizes	O
the	O
enzyme	O
on	O
the	O
platelet	B-Cellular_component
surface	I-Cellular_component
and	O
accelerates	O
the	O
hydrolysis	O
of	O
PAR	O
-	O
1	O
(	O
9	O
)	O
.	O

PAR	O
-	O
1	O
and	O
P2Y12	O
cross	O
-	O
react	O
in	O
platelet	B-Cell
activation	O
,	O
and	O
Galphaq	O
and	O
Galphai	O
-	O
coupled	O
receptors	O
are	O
involved	O
in	O
this	O
process	O
.	O

Thrombin	O
-	O
dependent	O
platelet	B-Cell
aggregation	O
is	O
mediated	O
in	O
part	O
by	O
secreted	O
ADP	O
,	O
acting	O
on	O
the	O
Galphai	O
-	O
linked	O
ADP	O
receptor	O
.	O

By	O
blocking	O
Galphaq	O
via	O
PAR	O
-	O
1	O
and	O
Gbetai	O
via	O
P2Y12	O
,	O
combined	O
inhibition	O
of	O
thrombin	O
and	O
P2Y12	O
receptors	O
leads	O
to	O
a	O
synergistic	O
inhibitory	O
effect	O
on	O
thrombin	O
-	O
induced	O
platelet	B-Cell
aggregation	O
(	O
10	O
)	O
.	O

5	O
-	O
HT	O
is	O
a	O
vasoconstrictor	O
agent	O
that	O
binds	O
to	O
5HT	O
-	O
2A	O
receptors	O
and	O
amplifies	O
the	O
platelet	B-Cell
response	O
by	O
stimulating	O
shape	O
change	O
and	O
enhancing	O
platelet	B-Cell
recruitment	O
at	O
sites	O
of	O
injury	O
(	O
3	O
)	O
.	O

It	O
may	O
also	O
play	O
a	O
pro	O
-	O
coagulant	O
role	O
by	O
promoting	O
the	O
retention	O
of	O
fibrinogen	O
and	O
thrombospondin	O
on	O
the	O
platelet	B-Cellular_component
surface	I-Cellular_component
.	O

Intraplatelet	B-Immaterial_anatomical_entity
5	O
-	O
HT	O
stores	O
are	O
implicated	O
in	O
shear	O
-	O
induced	O
platelet	B-Cell
aggregation	O
and	O
thrombus	B-Pathological_formation
propagation	O
(	O
3	O
)	O
.	O

